CELC - Newly FDA -Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guideli
CELC - Newly FDA -Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer - Click For Release
Story updates
12:34:49 PM UTC
SquawkNews
CELC newly FDA-approved revtorpyk™ (gedatolisib) included in the National comprehensive cancer network® (nccn®) clinical practice guidelines for hr+/her2- locally advanced or metastatic breast cancer Celcuity - FDA approves revtorpyk for hr+/her2- advanced breast cancer without pik3ca mutation on July 14, 2026 - Revtorpyk expected to be commercially available in U.S. in late Q3 2026
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.